1. Home
  2. BMEA vs FOSL Comparison

BMEA vs FOSL Comparison

Compare BMEA & FOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • FOSL
  • Stock Information
  • Founded
  • BMEA 2017
  • FOSL 1984
  • Country
  • BMEA United States
  • FOSL United States
  • Employees
  • BMEA N/A
  • FOSL N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • FOSL Consumer Specialties
  • Sector
  • BMEA Health Care
  • FOSL Consumer Discretionary
  • Exchange
  • BMEA Nasdaq
  • FOSL Nasdaq
  • Market Cap
  • BMEA 103.5M
  • FOSL 100.0M
  • IPO Year
  • BMEA 2021
  • FOSL 1993
  • Fundamental
  • Price
  • BMEA $1.83
  • FOSL $2.92
  • Analyst Decision
  • BMEA Strong Buy
  • FOSL Strong Buy
  • Analyst Count
  • BMEA 10
  • FOSL 1
  • Target Price
  • BMEA $17.70
  • FOSL $5.00
  • AVG Volume (30 Days)
  • BMEA 683.1K
  • FOSL 1.1M
  • Earning Date
  • BMEA 08-05-2025
  • FOSL 08-13-2025
  • Dividend Yield
  • BMEA N/A
  • FOSL N/A
  • EPS Growth
  • BMEA N/A
  • FOSL N/A
  • EPS
  • BMEA N/A
  • FOSL N/A
  • Revenue
  • BMEA N/A
  • FOSL $1,083,797,000.00
  • Revenue This Year
  • BMEA N/A
  • FOSL N/A
  • Revenue Next Year
  • BMEA N/A
  • FOSL N/A
  • P/E Ratio
  • BMEA N/A
  • FOSL N/A
  • Revenue Growth
  • BMEA N/A
  • FOSL N/A
  • 52 Week Low
  • BMEA $1.29
  • FOSL $0.86
  • 52 Week High
  • BMEA $13.07
  • FOSL $3.58
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 56.62
  • FOSL 72.73
  • Support Level
  • BMEA $1.51
  • FOSL $1.63
  • Resistance Level
  • BMEA $1.86
  • FOSL $3.31
  • Average True Range (ATR)
  • BMEA 0.10
  • FOSL 0.28
  • MACD
  • BMEA 0.03
  • FOSL 0.11
  • Stochastic Oscillator
  • BMEA 91.67
  • FOSL 66.83

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

Share on Social Networks: